Tocilizumab in MOG-antibody spectrum disorder: a case report

G Novi; M Gastaldi; D Franciotta; G Pesce; L Benedetti; A Uccelli

doi:10.1016/j.msard.2018.11.012

Tocilizumab in MOG-antibody spectrum disorder: a case report

G Novi, M Gastaldi, D Franciotta, G Pesce, L Benedetti, A Uccelli

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: Myelin oligodendrocyte glycoprotein antibody-related spectrum disorders (MOG-SD) are a heterogeneous group of inflammatory demyelinating diseases of the central nervous system, usually responsive to conventional immunosuppressive therapies. However, knowledge about treatment of non-responder patients is scarce.

METHODS: We report on a 20-year-old MOG-SD patient who experienced clinical deterioration despite rituximab-induced B-cell depletion.

RESULTS: Rescue therapy with tocilizumab (TCZ) prevented further relapses, with reduction of spinal-cord load on MRI, and a remarkable reduction of disability at the two-year follow-up.

CONCLUSION: Our observations suggest that TCZ could induce clinico-radiologic improvements, which make it as an option for the treatment of MOG-SD.

Original language	English
Pages (from-to)	312-314
Number of pages	3
Journal	Multiple Sclerosis and Related Disorders
Volume	27
DOIs	https://doi.org/10.1016/j.msard.2018.11.012
Publication status	E-pub ahead of print - Nov 13 2018

Access to Document

10.1016/j.msard.2018.11.012

Fingerprint Dive into the research topics of 'Tocilizumab in MOG-antibody spectrum disorder: a case report'. Together they form a unique fingerprint.

Cite this

@article{95157b8bb09742afa422b49796bf079c,

title = "Tocilizumab in MOG-antibody spectrum disorder: a case report",

abstract = "BACKGROUND: Myelin oligodendrocyte glycoprotein antibody-related spectrum disorders (MOG-SD) are a heterogeneous group of inflammatory demyelinating diseases of the central nervous system, usually responsive to conventional immunosuppressive therapies. However, knowledge about treatment of non-responder patients is scarce.METHODS: We report on a 20-year-old MOG-SD patient who experienced clinical deterioration despite rituximab-induced B-cell depletion.RESULTS: Rescue therapy with tocilizumab (TCZ) prevented further relapses, with reduction of spinal-cord load on MRI, and a remarkable reduction of disability at the two-year follow-up.CONCLUSION: Our observations suggest that TCZ could induce clinico-radiologic improvements, which make it as an option for the treatment of MOG-SD.",

author = "G Novi and M Gastaldi and D Franciotta and G Pesce and L Benedetti and A Uccelli",

note = "Copyright {\textcopyright} 2018. Published by Elsevier B.V.",

year = "2018",

month = nov,

day = "13",

doi = "10.1016/j.msard.2018.11.012",

language = "English",

volume = "27",

pages = "312--314",

journal = "Multiple Sclerosis and Related Disorders",

issn = "2211-0348",

publisher = "Elsevier",

}

TY - JOUR

T1 - Tocilizumab in MOG-antibody spectrum disorder

T2 - a case report

AU - Novi, G

AU - Gastaldi, M

AU - Franciotta, D

AU - Pesce, G

AU - Benedetti, L

AU - Uccelli, A

PY - 2018/11/13

Y1 - 2018/11/13

N2 - BACKGROUND: Myelin oligodendrocyte glycoprotein antibody-related spectrum disorders (MOG-SD) are a heterogeneous group of inflammatory demyelinating diseases of the central nervous system, usually responsive to conventional immunosuppressive therapies. However, knowledge about treatment of non-responder patients is scarce.METHODS: We report on a 20-year-old MOG-SD patient who experienced clinical deterioration despite rituximab-induced B-cell depletion.RESULTS: Rescue therapy with tocilizumab (TCZ) prevented further relapses, with reduction of spinal-cord load on MRI, and a remarkable reduction of disability at the two-year follow-up.CONCLUSION: Our observations suggest that TCZ could induce clinico-radiologic improvements, which make it as an option for the treatment of MOG-SD.

AB - BACKGROUND: Myelin oligodendrocyte glycoprotein antibody-related spectrum disorders (MOG-SD) are a heterogeneous group of inflammatory demyelinating diseases of the central nervous system, usually responsive to conventional immunosuppressive therapies. However, knowledge about treatment of non-responder patients is scarce.METHODS: We report on a 20-year-old MOG-SD patient who experienced clinical deterioration despite rituximab-induced B-cell depletion.RESULTS: Rescue therapy with tocilizumab (TCZ) prevented further relapses, with reduction of spinal-cord load on MRI, and a remarkable reduction of disability at the two-year follow-up.CONCLUSION: Our observations suggest that TCZ could induce clinico-radiologic improvements, which make it as an option for the treatment of MOG-SD.

U2 - 10.1016/j.msard.2018.11.012

DO - 10.1016/j.msard.2018.11.012

M3 - Article

C2 - 30469022

VL - 27

SP - 312

EP - 314

JO - Multiple Sclerosis and Related Disorders

JF - Multiple Sclerosis and Related Disorders

SN - 2211-0348

ER -